ÂÜÀòÂÒÂ×

Dr. Christoph Rosenbohm is the Chief Technology Officer at Ceptur Therapeutics. He was previously Head of Oligonucleotides Technical Development at Roche (2019-2021), Head of Synthesis & Optimization at Roche Innovation Center Copenhagen (2014-2019), and Sr. Director of Research Operation at Santaris Pharma (2010-2014). Dr. Rosenbohm is the author of more than 30 scientific publications and is an inventor on more than 15 patents/applications in the oligonucleotides field

Dr. Rosenbohm holds a Master of Science and a Ph.D. in Organic Chemistry from the University of Southern Denmark (the lab of Prof. Jesper Wengel). After his Ph.D., Christoph worked as a post-doctoral fellow at the Danish Technical Univerisity. In addition, Christoph holds an executive MBA in Technology, Market, and Organisation from Copenhagen Business School.